Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Non Operating Income (2019 - 2025)

Allogene Therapeutics' Non Operating Income history spans 7 years, with the latest figure at $9.4 million for Q3 2025.

  • For Q3 2025, Non Operating Income rose 71.87% year-over-year to $9.4 million; the TTM value through Sep 2025 reached $15.8 million, up 94.84%, while the annual FY2024 figure was $16.1 million, 190.0% up from the prior year.
  • Non Operating Income for Q3 2025 was $9.4 million at Allogene Therapeutics, up from -$43000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $9.4 million in Q3 2025 and bottomed at -$8.3 million in Q2 2023.
  • The 5-year median for Non Operating Income is $186000.0 (2021), against an average of $618789.5.
  • The largest YoY upside for Non Operating Income was 391.94% in 2022 against a maximum downside of 4050.54% in 2022.
  • A 5-year view of Non Operating Income shows it stood at -$1.8 million in 2021, then soared by 51.3% to -$880000.0 in 2022, then plummeted by 687.95% to -$6.9 million in 2023, then skyrocketed by 114.34% to $994000.0 in 2024, then surged by 847.69% to $9.4 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Non Operating Income are $9.4 million (Q3 2025), -$43000.0 (Q2 2025), and $5.5 million (Q1 2025).